MGI Pharma MOGN New patents, anti cancer Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (1689)	7/27/2006 1:38:12 AM
From: Icebrg	Read Replies (1) of 1826

MGI Pharma "neutral," target price reduced Wednesday, July 26, 2006 7:12:26 AM ET Robert W. Baird NEW YORK, July 26 (newratings.com) - Analysts at Robert W Baird maintain their "neutral" rating on MGI Pharma Inc (MOGN.NAS), while reducing their estimates for the company. The target price has been reduced from $18 to $16. In a research note published this morning, the analysts mention that the company has reduced its Aloxi guidance for FY06 by $30-$35 million, with the Aloxi sales forecast for Q406 being reduced from $83 million to $50-$70 million. MGI Pharma has indicated an accelerated trend of physicians' adoption of generic Zofran, and has outlined the market impact on Aloxi. The EPS estimate for FY07 has been reduced from $0.55 to $0.48.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next